Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490545 | 0.88 | OPRD1 (0.47) | OPRD1KCNH2CYP2D6OPRK1ALDH1A1 | |
| SCHEMBL5094922 | 0.84 | PDK2 (0.39) | KCNH2ALDH1A1ROCK2PDK2ROCK1 | |
| SCHEMBL490378 | 0.81 | ROCK2 (0.48) | OPRD1KCNH2CYP2D6OPRK1ROCK2 | |
| SCHEMBL5103258 | 0.76 | OPRD1 (0.47) | OPRD1KCNH2CYP2D6OPRK1 | |
| SCHEMBL3384454 | 0.75 | SETD7 (0.44) | OPRD1KCNH2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5094869 | 0.74 | PARP14 (0.37) | ALDH1A1CHRM3CHRM1SMN1; SMN2 | |
| SCHEMBL5090960 | 0.74 | OPRD1 (0.45) | OPRD1KCNH2CYP2D6OPRK1 | |
| SCHEMBL5096902 | 0.73 | OPRD1 (0.48) | OPRD1KCNH2CYP2D6OPRK1ALDH1A1 | |
| SCHEMBL5197746 | 0.73 | CHRM1 (0.36) | OPRD1KCNH2CHRM3CHRM1 | |
| SCHEMBL490144 | 0.71 | OPRD1 (0.52) | OPRD1KCNH2CYP2D6OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | CARSON JOHN R | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135522-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | OPRD1 1/4885KCNH2 618/4885CYP2D6 359/4885 |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | OPRD1 1/4885KCNH2 618/4885CYP2D6 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.